Item 8.01. Other Events. OnJanuary 6, 2022 ,2seventy bio, Inc. issued a press release announcing that it has entered into an option and license agreement with Novo Nordisk for the joint research and development of an in vivo gene editing treatment for hemophilia A and that it has entered into an agreement with Genevant Sciences for access to Genevant's industry-leading LNP technology platform for use in the collaboration with Novo Nordisk. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of2seventy bio, Inc. , datedJanuary 6, 2022 .
__________________
© Edgar Online, source